Skip to main content
. 2017 Oct 19;61(3):222–227. doi: 10.3164/jcbn.17-57

Fig. 2.

Fig. 2

(A) Percentages of CINV in patients with NK1 antagonist or without after TACE or HAIC. The Pearson’s chi-square test was used to compare the percentages in each group. *p<0.05. (B) Average duration of CINV in HCC patients by treatment group. The Mann-Whitney U test was used to compare the average duration in each group.